A method for treating cancer with a combination of a chemotherapy agent and a composition that includes quercetin. The composition can also include one or more of vitamin B3, vitamin C, and folic acid.

A method for treating cancer with a combination of a chemotherapy agent and a composition that includes quercetin. The composition can also include one or more of vitamin B3, vitamin C, and folic acid.

The present invention relates generally to a therapeutic protocol for treating a subject having cancer. Taught herein is a method of treating cancer or reducing the risk of recurrence of cancer in a subject following an anti-cancer therapy.

The present invention relates generally to a therapeutic protocol for treating a subject having cancer. Taught herein is a method of treating cancer or reducing the risk of recurrence of cancer in a subject following an anti-cancer therapy.

An anti-neoplastic combined pharmaceutical composition and application thereof. The combined pharmaceutical composition is prepared from plasmodia and chemotherapeutic drugs. The combined pharmaceutical composition combines chemotherapy with Plasmodium immunotherapy, has high biosafety, has stronger antineoplastic activity than single chemotherapy or single Plasmodium immunotherapy, can prolong the lifetime of cancer patients, and provides a new strategy and idea for cancer treatment. Moreover, the dosage of the chemotherapy drugs can be reduced, toxic and side effects caused by the chemotherapy drugs are reduced, and treatment costs of tumor patients are reduced. In addition, the combined pharmaceutical composition can promote release of a tumor antigen, induces a stronger anti-tumor specific immune response, and exerts the continuous synergistic effect of immunotherapy and chemotherapy.

An anti-neoplastic combined pharmaceutical composition and application thereof. The combined pharmaceutical composition is prepared from plasmodia and chemotherapeutic drugs. The combined pharmaceutical composition combines chemotherapy with Plasmodium immunotherapy, has high biosafety, has stronger antineoplastic activity than single chemotherapy or single Plasmodium immunotherapy, can prolong the lifetime of cancer patients, and provides a new strategy and idea for cancer treatment. Moreover, the dosage of the chemotherapy drugs can be reduced, toxic and side effects caused by the chemotherapy drugs are reduced, and treatment costs of tumor patients are reduced. In addition, the combined pharmaceutical composition can promote release of a tumor antigen, induces a stronger anti-tumor specific immune response, and exerts the continuous synergistic effect of immunotherapy and chemotherapy.

The present specification relates generally to a therapeutic protocol for treating a subject having cancer. Taught herein is a method of treating cancer or reducing the risk of recurrence of cancer in a subject following an anti-cancer therapy.

The present specification relates generally to a therapeutic protocol for treating a subject having cancer. Taught herein is a method of treating cancer or reducing the risk of recurrence of cancer in a subject following an anti-cancer therapy.

A method of predicting and treating doxorubicin-resistant cancer including determining expression of Myc-regulated genes and MPST transcription levels. The method further includes classifying the cancer as doxorubicin resistant when either Myc transcription is higher than IMR-32 transcription or MPST transcription levels are above a predetermined amount. The method further includes administering an effective amount of AP39 for ameliorating the doxorubicin-induced cardiotoxicity by combing doxorubicin with AP39.

A method of predicting and treating doxorubicin-resistant cancer including determining expression of Myc-regulated genes and MPST transcription levels. The method further includes classifying the cancer as doxorubicin resistant when either Myc transcription is higher than IMR-32 transcription or MPST transcription levels are above a predetermined amount. The method further includes administering an effective amount of AP39 for ameliorating the doxorubicin-induced cardiotoxicity by combing doxorubicin with AP39.